Rapid infectious disease test

COVID-19flufor antigens

Verify potential infection quickly with a rapid microfluidic assay that provides actionable and lab-comparable results in 12 mins for patients suspected of Flu and/or COVID-19, to help decision making and guide treatment Test benefits Microfluidic immunofluorescence assay Easy to implement at point of care No refrigeration storage required: room temperature storage (2°C to 30 °C) Portable Instrument for near-patient testing Minimal handling steps Test workflow The Instrument and Test Strips are integrated with several quality control checks to ensure the Instrument and Test are functioning correctly for every test run. The workflow process is comprised of a simple sample prep along with step-by-step guidance of the Instrument to report a patient result in under 12 minutes from sample application. Test performance In clinical studies, the LumiraDx SARS-COV-2 & Flu A/B test demonstrated up to 95.5%, 83.3% and 80.0% positive agreement versus RT-PCR for detection of SARS-COV-2, Flu A and Flu B respectively.